Zeitschriftenartikel zum Thema „Myers, Kevin“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-47 Zeitschriftenartikel für die Forschung zum Thema "Myers, Kevin" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Macpherson, Jim. „Struggles for a Past: Irish and Afro-Caribbean Histories in England, 1951–2000. By Kevin Myers“. Twentieth Century British History 30, Nr. 4 (18.09.2018): 618–20. http://dx.doi.org/10.1093/tcbh/hwy030.
Der volle Inhalt der QuelleGerrard, Jessica. „Struggles for a past: Irish and Afro-Caribbean histories in England, 1951–2000, by Kevin Myers“. History of Education 46, Nr. 4 (09.05.2016): 533–34. http://dx.doi.org/10.1080/0046760x.2016.1181798.
Der volle Inhalt der QuelleArriens, C., A. Askanase, R. Furie, E. F. Morand, R. Van Vollenhoven, K. Connors, M. Davey et al. „AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1463.1–1463. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3881.
Der volle Inhalt der QuelleChoy, E., S. Henning, M. Brazil, K. Pollock, L. Groves, D. Sugrue und J. Houghton. „AB0347 TREATMENT RESPONSE WITH ABATACEPT PLUS METHOTREXATE TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1299.1–1299. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2356.
Der volle Inhalt der QuelleCurtis, J., K. Winthrop, B. Chan, S. Siegel, J. Stark, R. Suruki, R. Bohn et al. „FRI0314 ANNUAL DIAGNOSTIC PREVALENCE OF ANKYLOSING SPONDYLITIS (AS) IN THE UNITED STATES USING MEDICARE AND MARKETSCAN DATA“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 747.1–748. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4246.
Der volle Inhalt der QuelleKorman, N. J., T. Passeron, K. B. Gordon, Y. Okubo, J. Bagel, H. Sofen, R. B. Warren et al. „AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1774–75. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1533.
Der volle Inhalt der QuelleDeodhar, A., K. Winthrop, R. Bohn, B. Chan, R. Suruki, J. Stark, H. Yun, S. Siegel, L. Chen und J. Curtis. „SAT0370 TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS: AN ANALYSIS OF THREE US CLAIMS DATABASES“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1132.1–1133. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4201.
Der volle Inhalt der QuelleWinthrop, K., P. Nash, K. Yamaoka, E. Mysler, L. Calabrese, N. Khan, J. J. Enejosa, Y. Song, J. Suboticki und J. R. Curtis. „THU0218 INCIDENCE AND RISK FACTORS FOR HERPES ZOSTER IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING UPADACITINIB“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 335–36. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2744.
Der volle Inhalt der QuelleAletaha, D., P. J. Mease, R. Lippe, F. Behrens, D. Haaland, P. Palominos, A. Lertratanakul et al. „POS1026 PREDICTORS FOR ACHIEVEMENT OF LOW DISEASE ACTIVITY AT WEEK 56 IN PATIENTS WITH PSORIATIC ARTHRITIS WHO RECEIVED UPADACITINIB 15 MG ONCE DAILY: POOLED ANALYSIS OF TWO PHASE 3 STUDIES“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 824.2–825. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1291.
Der volle Inhalt der QuelleBaraliakos, X., R. Ranza, A. Ostor, F. Ciccia, L. Coates, S. Rednic, J. A. Walsh et al. „POS0934 EFFICACY OF UPADACITINIB ON PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT DEFINED BY INVESTIGATOR ASSESSMENT AND PRO-BASED CRITERIA: RESULTS FROM TWO PHASE 3 STUDIES“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 768. http://dx.doi.org/10.1136/annrheumdis-2022-eular.722.
Der volle Inhalt der QuelleRoth, Andreas. „Francis Stuart’s broadcasts from Germany, 1942—4: some new evidence“. Irish Historical Studies 32, Nr. 127 (Mai 2001): 408–22. http://dx.doi.org/10.1017/s002112140001508x.
Der volle Inhalt der QuelleGottlieb, A. B., F. Behrens, P. Nash, J. F. Merola, K. Ding, P. Pellet, L. Pricop und I. Mcinnes. „FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 763.2–764. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4736.
Der volle Inhalt der QuelleLininger, N., S. Siegel, S. Kiwalkar, K. Winthrop, A. Ortega Loayza und A. Deodhar. „FRI0555 DO TNF INHIBITORS DECREASE RISK OF INCIDENT PSORIATIC ARTHRITIS IN PSORIASIS PATIENTS COMPARED TO THOSE TREATED WITH METHOTREXATE ALONE?“ Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 879.2–880. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4983.
Der volle Inhalt der QuelleTurnage, Richard H., John L. Lanoue, Kevin M. Kadesky, Yan Meng und Stuart I. Myers. „Thromboxane A2 mediates increased pulmonary microvascular permeability after intestinal reperfusion“. Journal of Applied Physiology 82, Nr. 2 (01.02.1997): 592–98. http://dx.doi.org/10.1152/jappl.1997.82.2.592.
Der volle Inhalt der QuelleStefanovska, Bojana, Kevin Lin, Benjamin Troness, Chad Myers und Reuben Harris. „Abstract P2-17-01: Targeted CRISPR screen to identify synthetic lethal combinations between APOBEC3B and DNA repair“. Cancer Research 83, Nr. 5_Supplement (01.03.2023): P2–17–01—P2–17–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-17-01.
Der volle Inhalt der QuelleMcinnes, I., F. Behrens, P. J. Mease, A. Kavanaugh, C. T. Ritchlin, P. Nash, J. Gratacos-Masmitja et al. „OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 142–43. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4129.
Der volle Inhalt der QuelleGenovese, M. C., K. Winthrop, Y. Tanaka, T. Takeuchi, A. Kivitz, F. Matzkies, L. Ye et al. „THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 324–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.267.
Der volle Inhalt der QuelleBykerk, V., A. B. Gottlieb, K. Reich, Y. Tanaka, K. Winthrop, C. Popova, N. Tilt und A. Blauvelt. „FRI0087 DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 621.1–621. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1682.
Der volle Inhalt der QuelleKITLV, Redactie. „Book Reviews“. New West Indian Guide / Nieuwe West-Indische Gids 62, Nr. 3-4 (01.01.1988): 165–209. http://dx.doi.org/10.1163/13822373-90002043.
Der volle Inhalt der QuelleMease, P. J., A. Kavanaugh, D. D. Gladman, O. Fitzgerald, E. Soriano, P. Nash, D. Feng et al. „AB0529 CHARACTERIZATION OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: POST-HOC ANALYSIS FROM TWO PHASE 3 TRIALS“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 1294–95. http://dx.doi.org/10.1136/annrheumdis-2021-eular.574.
Der volle Inhalt der QuelleHirano, A., W. Fujii, A. Sakashita, K. Baßler, M. Kadoya, A. Omoto, W. Fukuda et al. „POS0151 SINGLE-CELL RNA SEQUENCING OF BRONCHOALVEOLAR LAVAGE FLUID AND BLOOD REVEALS DISEASE-SPECIFIC CHARACTERISTICS OF IMMUNE CELLS IN CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE PATIENTS“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 296–97. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2875.
Der volle Inhalt der QuelleKavanaugh, A., P. J. Mease, K. Douglas, F. Behrens, D. Haaland, P. Palominos, A. Lertratanakul et al. „AB0547 ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIES“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 1306.2–1307. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2000.
Der volle Inhalt der QuelleMerola, J. F., I. Mcinnes, A. Kavanaugh, P. Nash, Z. Xue, V. Stakias, A. Eldred, S. Ciecinski, K. Douglas und L. Coates. „POS1029 EFFECTS OF TREATMENT WITH RISANKIZUMAB ON MINIMAL DISEASE ACTIVITY (MDA) AND DISEASE ACTIVITY IN PSORIATIC ARTHRITIS (DAPSA): AN ANALYSIS OF THE KEEPsAKE-1 AND -2 TRIALS“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 827. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1362.
Der volle Inhalt der QuelleMerrill, J. T., M. Smith, K. Thomas, C. Guthridge, N. Dominguez, S. Macwana, W. Dejager et al. „POS1154 PRE-TREATMENT DIFFERENTIALLY EXPRESSED METAGENES CHARACTERIZE SYSTEMIC LUPUS PATIENTS WHO SUBSEQUENTLY ACHIEVE CLINICAL RESPONSE TO BELIMUMAB“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 908–9. http://dx.doi.org/10.1136/annrheumdis-2023-eular.4022.
Der volle Inhalt der QuelleFujii, W., A. Sakashita, A. Hirano, K. Baßler, M. Kadoya, A. Omoto, W. Fukuda et al. „POS0616 THE CHARACTERISTICS OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE IN CONNECTIVE TISSUE DISEASES WITH SINGLE-CELL RNA SEQUENCING OF BRONCHOALVEOLAR LAVAGE FLUID“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 580.1–581. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2140.
Der volle Inhalt der QuelleGalloway, J., M. H. Buch, K. Yamaoka, C. Leatherwood, A. Pechonkina, I. Tiamiyu, D. Jiang et al. „OP0126 INFECTIONS AND SERIOUS INFECTIONS IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 70–71. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1416.
Der volle Inhalt der QuelleCostello, R. E., J. Humphreys, K. Winthrop und W. Dixon. „SAT0065 TIMING OF PNEUMOCOCCAL VACCINATIONS IN RELATION TO STARTING DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 965.1–966. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1157.
Der volle Inhalt der QuelleGenovese, M. C., J. S. Smolen, T. Takeuchi, G. R. Burmester, W. Deberdt, D. Schlichting, H. Song, D. Mo, C. Walls und K. Winthrop. „FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 642.1–643. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1723.
Der volle Inhalt der QuelleWinter, Timothy, Timothy Myers, Leandro Colli, Lea Jessop, Jiyeon Choi, Mitchell J. Machiela, Mark P. Purdue, Kevin Brown und Stephen Chanock. „Abstract 6154: Targeted CRISPRi screen identifies functional variants and novel target genes at multiple renal cell carcinoma (RCC) susceptibility loci“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 6154. http://dx.doi.org/10.1158/1538-7445.am2024-6154.
Der volle Inhalt der QuelleWinthrop, K., D. Gold, D. Henrohn, L. Wang, A. Shapiro, H. Shi, G. Citera und H. Schulze-Koops. „SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1007–8. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1432.
Der volle Inhalt der QuelleThakur, Rohit, Mai Xu, Alexandra Thornock, Hayley Sowards, Epring Long, Thomas Rheling, Karen Funderburk et al. „Abstract 5239: Integrative analysis of 3D chromatin organization at GWAS loci identifies RAPGEF1 as a melanoma susceptibility gene“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 5239. http://dx.doi.org/10.1158/1538-7445.am2023-5239.
Der volle Inhalt der QuelleHu, Fang Q., und Douglas M. Nark. „On a stabilization of the Ingard-Myers impedance boundary condition and its time domain implementation“. International Journal of Aeroacoustics 23, Nr. 3-4 (09.05.2024): 318–41. http://dx.doi.org/10.1177/1475472x241230649.
Der volle Inhalt der QuelleRims, C., V. Muir, K. Deane, S. Nagpal, N. Rao, F. Baribaud, G. Vratsanos et al. „THU0033 ALTERATIONS IN THE PHENOTYPIC LANDSCAPE AND SPECIFICITY OF CD4+ T CELLS IN CCP+ AT RISK SUBJECTS BEFORE THE ONSET OF RHEUMATOID ARTHRITIS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 230.1–230. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1918.
Der volle Inhalt der QuelleBurmester, G. R., K. Winthrop, R. Blanco, P. Nash, P. Goupille, V. F. Azevedo, C. Salvarani et al. „AB0522 SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS FROM THE PHASE 3 PROGRAM“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 1287–88. http://dx.doi.org/10.1136/annrheumdis-2021-eular.395.
Der volle Inhalt der QuelleHu, Fang, und Douglas M. Nark. „A time domain boundary element method for acoustic scattering by lined surfaces in a subsonic uniform mean flow“. Journal of the Acoustical Society of America 152, Nr. 4 (Oktober 2022): A118. http://dx.doi.org/10.1121/10.0015737.
Der volle Inhalt der QuelleAi, R., D. Boyle, D. Hammaker, K. Deane, V. M. Holers, A. Matti, W. Robinson et al. „OP0337 DIFFERENTIAL METHYLATION OF PERIPHERAL BLOOD ADAPTIVE IMMUNE CELLS IN INDIVIDUALS AT HIGH RISK FOR RA AND WITH EARLY RA COMPARED WITH CONTROLS IDENTIFIES PATHWAYS IMPORTANT IN TRANSITION TO ARTHRITIS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 207.2–207. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2989.
Der volle Inhalt der QuellePolinski, K., E. Bemis, K. Demoruelle, J. Seifert, T. Crume, F. Yang, W. Robinson et al. „SAT0596 ASSOCIATIONS BETWEEN CIRCULATING LIPID MEDIATORS AND INCIDENT INFLAMMATORY ARTHRITIS IN AN ANTI-CITRULLINATED PROTEIN ANTIBODY POSITIVE POPULATION“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1256.1–1256. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1884.
Der volle Inhalt der QuelleJenkins, Rhys. „R. Evan Ellis, China on the Ground in Latin America: Challenges for the Chinese and Impacts on the Region (Basingstoke and New York: Palgrave Macmillan, 2014), pp. xiii + 320, £72.00, hb. - Kevin P. Gallagher, The China Triangle: Latin America's China Boom and the Fate of the Washington Consensus (Oxford and New York: Oxford University Press, 2016), pp. xvii + 232, £18.99; $27.95, hb. - Margaret Myers and Carol Wise (eds.), The Political Economy of China–Latin America Relations in the New Millennium: Brave New World (New York and London: Routledge, 2017), pp. vii + 293, £29.99, pb. - Yanran Xu, China's Strategic Partnerships in Latin America: Case Studies of China's Oil Diplomacy in Argentina, Brazil, Mexico, and Venezuela, 1991–2015 (Lanham, MD: Lexington Books, 2017), pp. ix + 157, £52.95, hb.“ Journal of Latin American Studies 51, Nr. 1 (Februar 2019): 187–91. http://dx.doi.org/10.1017/s0022216x19000014.
Der volle Inhalt der QuelleLuo, Rui, Weelic Chong, Zhenchao Zhang, Maysa Abu-Khalaf, Daniel Silver, Frederick Fellin, Rebecca Jaslow et al. „Abstract P5-06-05: Whole-genome bisulfite sequencing of single circulating tumor cells identifies cellular methylation heterogeneity in metastatic breast cancer“. Cancer Research 83, Nr. 5_Supplement (01.03.2023): P5–06–05—P5–06–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-06-05.
Der volle Inhalt der QuelleKITLV, Redactie. „Book Reviews“. New West Indian Guide / Nieuwe West-Indische Gids 70, Nr. 1-2 (01.01.1996): 133–203. http://dx.doi.org/10.1163/13822373-90002634.
Der volle Inhalt der QuelleHengel, Richard L., Sujatha Krishnan, Jonathan A. Rosenberg, Timothy E. Ritter, Kathy A. Baker, Lucinda J. Van Anglen, Amy Guo, Mielad Moosapanah, Min Yang und Kevin W. Garey. „685. Early Experience with a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile“. Open Forum Infectious Diseases 10, Supplement_2 (27.11.2023). http://dx.doi.org/10.1093/ofid/ofad500.747.
Der volle Inhalt der Quelle„Recensions / Reviews“. Canadian Journal of Political Science 34, Nr. 4 (Dezember 2001): 845–924. http://dx.doi.org/10.1017/s0008423901778110.
Der volle Inhalt der QuelleRamos, Gabriel Teixeira. „CARTOGRAFIAS E MOVIMENTOS“. Revista Jatobá 1 (18.12.2019). http://dx.doi.org/10.54686/revjat.v1i.61326.
Der volle Inhalt der QuelleCashman, Dorothy Ann. „“This receipt is as safe as the Bank”: Reading Irish Culinary Manuscripts“. M/C Journal 16, Nr. 3 (23.06.2013). http://dx.doi.org/10.5204/mcj.616.
Der volle Inhalt der QuelleBrien, Donna Lee. „Demon Monsters or Misunderstood Casualties?“ M/C Journal 24, Nr. 5 (05.10.2021). http://dx.doi.org/10.5204/mcj.2845.
Der volle Inhalt der QuelleWilson, Shaun. „Situating Conceptuality in Non-Fungible Token Art“. M/C Journal 25, Nr. 2 (25.04.2022). http://dx.doi.org/10.5204/mcj.2887.
Der volle Inhalt der QuelleRyder, Paul, und Jonathan Foye. „Whose Speech Is It Anyway? Ownership, Authorship, and the Redfern Address“. M/C Journal 20, Nr. 5 (13.10.2017). http://dx.doi.org/10.5204/mcj.1228.
Der volle Inhalt der Quelle